Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa

Journal of Ophthalmology

Volumn 2017, Issue , 2017, Pages

  Pielen, Amelie ^a,b   Bühler, Anima Desiree ^a,b   Heinzelmann, Sonja Ute ^b   Böhringer, Daniel ^b   Ness, Thomas ^b   Junker, Bernd ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85042847178     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2017/5831682     Document Type: Article

References (36)

1. A. Pielen, N. Feltgen, C. Isserstedt, J. Callizo, B. Junker, C. Schmucker, "Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: A systematic review, " PloS One, vol. 8, no. 10, article e78538, 2013.
2. T. Braithwaite, A. A. Nanji, K. Lindsley, P. B. Greenberg, "Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion, " Cochrane Database of Systematic Reviews, no. 5, article CD007325, 2014.
3. A. R. Berger, A. F. Cruess, F. Altomare, et al., "Optimal treatment of retinal vein occlusion: Canadian expert consensus, " Ophthalmologica Journal International Ophtalmologie International Journal Ophthalmology Zeitschrift Für Augenheilkunde, vol. 234, pp. 6-25, 2015.
4. P. A. Campochiaro, J. S. Heier, L. Feiner, et al., "Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study, " Ophthalmology, vol. 117, pp. 1102.e1-1112.e1, 2010.
5. D. M. Brown, P. A. Campochiaro, R. P. Singh, et al., "Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study, " Ophthalmology, vol. 117, pp. 1124.e1-1133.e1, 2010.
6. D. M. Brown, P. A. Campochiaro, R. B. Bhisitkul, et al., "Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study, " Ophthalmology, vol. 118, pp. 1594-1602, 2011.
7. P. A. Campochiaro, D. M. Brown, C. C. Awh, et al., "Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study, " Ophthalmology, vol. 118, pp. 2041-2049, 2011.
8. F. G. Holz, J. Roider, Y. Ogura, et al., "VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study, " The British Journal of Ophthalmology, vol. 97, pp. 278-284, 2013.
9. J. F. Korobelnik, F. G. Holz, J. Roider, et al., "Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: One-year results of the phase 3 GALILEO study, " Ophthalmology, vol. 121, pp. 202-208, 2014.
10. Y. Ogura, J. Roider, J. F. Korobelnik, et al., "Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study, " American Journal of Ophthalmology, vol. 158, no. 5, pp. 1032-1038, 2014.
11. D. Boyer, J. Heier, D. M. Brown, et al., "Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: Six-month results of the phase 3 COPERNICUS study, " Ophthalmology, vol. 119, pp. 1024-1032, 2012.
12. D. M. Brown, J. S. Heier, W. L. Clark, et al., "Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study, " American Journal of Ophthalmology, vol. 155, pp. 429.e7-437.e7, 2013.
13. P. A. Campochiaro, W. L. Clark, D. S. Boyer, et al., "Intravitreal aflibercept for macular edema following branch retinal vein occlusion: The 24-week results of the VIBRANT study, " Ophthalmology, vol. 122, pp. 538-544, 2015.
14. D. L. Epstein, P. V. Algvere, G. von Wendt, S. Seregard, A. Kvanta, "Bevacizumab for macular edema in central retinal vein occlusion: A prospective, randomized, doublemasked clinical study, " Ophthalmology, vol. 119, pp. 1184-1189, 2012.
15. D. L. Epstein, P. V. Algvere, G. von Wendt, S. Seregard, A. Kvanta, "Benefit from bevacizumab for macular edema in central retinal vein occlusion: Twelve-month results of a prospective, randomized study, " Ophthalmology, vol. 119, pp. 2587-2591, 2012.
16. J. A. Haller, F. Bandello, R. Belfort, et al., "Randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion, " Ophthalmology, vol. 117, pp. 1134.e3-1146.e3, 2010.
17. J. A. Haller, F. Bandello, R. Belfort, et al., "Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results, " Ophthalmology, vol. 118, pp. 2453-2460, 2011.
18. Germany Ophthalmology Society and Retina Society, "Professional Asociation of German Ophthalmologists. [statement of the German Ophthalmology Society, the Retina Society and the Professional Association of German Ophthalmologists for the treatment of macular edema in retinal vein occlusion: Therapeutic strategies], " Ophthalmol Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, vol. 109, pp. 818-831, 2012.
19. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion-full text view-ClinicalTrials.gov, " October 2016, https://clinicaltrials.gov/ct2/show/NCT01427751term=NCT01427751&rank=1.
20. L. O. Hattenbach, N. Feltgen, T. Bertelmann, et al., "Head-tohead comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B), " Acta Ophthalmologica, 2017.
21. H. Hoerauf, N. Feltgen, C. Weiss, et al., "Clinical efficacy and safety of Ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): A European label study, " American Journal of Ophthalmology, vol. 169, pp. 258-267, 2016.
22. M. Kim, D. H. Lee, S. H. Byeon, H. J. Koh, S. S. Kim, S. C. Lee, "Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion, " The British Journal of Ophthalmology, vol. 99, pp. 1271-1276, 2015.
23. C. Chiquet, C. Dupuy, A. M. Bron, et al., "Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: A 12-month follow-up study, " Graefes Archive Clinical and Experimental Ophthalmology Albrecht von Graefes Archiv Klinische Experimentelle Ophthalmologie, vol. 253, pp. 2095-2102, 2015.
24. A. Bajor, A. Pielen, L. Danzmann, "Retinal vein occlusionwhich treatment when, " Klinische Monatsblätter für Augenheilkunde, 2017.
25. N. Feltgen and A. Pielen, "Retinal vein occlusion: Therapy of retinal vein occlusion, " Ophthalmology Zeitchrift Deutschen Ophthalmologischen Gesellschaft, vol. 112, pp. 695-704, 2015, quiz 705-706.
26. G. Coscas, A. Loewenstein, A. Augustin, et al., "Management of retinal vein occlusion-consensus document, " Ophthalmologica Journal International Ophtalmologie International Journal Ophthalmology Zeitschrift Für Augenheilkunde, vol. 226, pp. 4-28, 2011.
27. J. S. Pulido, C. J. Flaxel, R. A. Adelman, L. Hyman, J. C. Folk, T. W. Olsen, "Retinal vein occlusions preferred practice pattern( ® ) guidelines, " Ophthalmology, vol. 123, pp. 182-208, 2016.
28. C. Ehlken, S. Jungmann, D. Böhringer, H. T. Agostini, B. Junker, A. Pielen, "Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD, " Eye London England, vol. 28, pp. 538-545, 2014.
29. K. Abri Aghdam, F. Seidensticker, A. Pielen, C. Framme, B. Junker, "The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography, " Lasers in Surgery and Medicine, vol. 48, pp. 668-677, 2016.
30. B. Sharareh, R. Gallemore, M. Taban, S. Onishi, J. Wallsh, "Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion, " Retina Philadelphia PA, vol. 33, pp. 1227-1231, 2013.
31. C. Chiquet, A. M. Bron, M. Straub, et al., "Retinal vein occlusions: Therapeutic switch in macular oedema treatment with a 12-month follow-up, " Ophthalmic Research, vol. 55, pp. 152-158, 2016.
32. W. J. Mayer, M. Remy, A. Wolf, et al., "Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema, " Ophthalmologica Journal International Ophtalmologie International Journal Ophthalmology Zeitschrift Für Augenheilkunde, vol. 228, pp. 110-116, 2012.
33. P. A. Campochiaro, R. Sophie, J. Pearlman, et al., "Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: The RETAIN study, " Ophthalmology, vol. 121, pp. 209-219, 2014.
34. R. Yamada, A. Nishida, M. Shimozono, et al., "Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion, " Japanese Journal of Ophthalmology, vol. 59, pp. 389-393, 2015.
35. R. Narayanan, B. Panchal, T. Das, J. Chhablani, S. Jalali, M. H. Ali, "A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report no. 1, " The British Journal of Ophthalmology, vol. 99, pp. 954-959, 2015.
36. Study of comparative treatments for retinal vein occlusion 2 (SCORE2)-full text View-ClinicalTrials.gov, " October 2016, https://clinicaltrials.gov/ct2/show/NCT01969708term=aflibe rcept+retinal+vein+occlusion&rank=3.